PE20150287A1 - Composicion farmaceutica que contiene un acido tetrahidrofolico - Google Patents

Composicion farmaceutica que contiene un acido tetrahidrofolico

Info

Publication number
PE20150287A1
PE20150287A1 PE2014002543A PE2014002543A PE20150287A1 PE 20150287 A1 PE20150287 A1 PE 20150287A1 PE 2014002543 A PE2014002543 A PE 2014002543A PE 2014002543 A PE2014002543 A PE 2014002543A PE 20150287 A1 PE20150287 A1 PE 20150287A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
tetrahydropholic
composition containing
progestagen
acid
Prior art date
Application number
PE2014002543A
Other languages
English (en)
Spanish (es)
Inventor
Kristina King
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150287(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20150287A1 publication Critical patent/PE20150287A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PE2014002543A 2006-07-06 2007-07-05 Composicion farmaceutica que contiene un acido tetrahidrofolico PE20150287A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06

Publications (1)

Publication Number Publication Date
PE20150287A1 true PE20150287A1 (es) 2015-03-15

Family

ID=36763829

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2014002543A PE20150287A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica que contiene un acido tetrahidrofolico
PE2007000867A PE20080273A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
PE2011002146A PE20120375A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica que contiene un acido tetrahidrofolico

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2007000867A PE20080273A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
PE2011002146A PE20120375A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica que contiene un acido tetrahidrofolico

Country Status (31)

Country Link
EP (2) EP2422774B1 (https=)
JP (1) JP2009542591A (https=)
KR (2) KR20130042638A (https=)
CN (3) CN101489563A (https=)
AR (2) AR061958A1 (https=)
AU (1) AU2007271449B2 (https=)
BR (1) BRPI0713565B8 (https=)
CA (2) CA2856344C (https=)
CL (1) CL2007001962A1 (https=)
CO (1) CO6150125A2 (https=)
CR (1) CR10549A (https=)
CU (1) CU20090004A7 (https=)
EC (1) ECSP099030A (https=)
ES (1) ES2626838T5 (https=)
GT (1) GT200900001A (https=)
IL (3) IL196027A0 (https=)
MA (1) MA30598B1 (https=)
MX (1) MX2009000079A (https=)
MY (1) MY169516A (https=)
NO (1) NO347567B1 (https=)
NZ (1) NZ573766A (https=)
PE (3) PE20150287A1 (https=)
PH (1) PH12012501774B1 (https=)
RU (2) RU2479306C2 (https=)
SG (1) SG188869A1 (https=)
TN (1) TNSN08543A1 (https=)
TW (2) TW201538161A (https=)
UA (2) UA100228C2 (https=)
UY (1) UY30462A1 (https=)
WO (1) WO2008003432A1 (https=)
ZA (4) ZA200900868B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
UY32836A (es) * 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
US20130137664A1 (en) * 2010-04-15 2013-05-30 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN107812195B (zh) * 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
CN105030779A (zh) * 2015-07-21 2015-11-11 福格森（武汉）生物科技股份有限公司 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
CN107446458A (zh) * 2017-08-04 2017-12-08 合众（佛山）化工有限公司 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
DK3781171T3 (da) 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
CN110237046B (zh) * 2019-03-29 2021-07-30 福格森（武汉）生物科技股份有限公司 一种l-5-甲基四氢叶酸微囊的制备方法
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
IT202100008834A1 (it) * 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
CN114569567B (zh) * 2021-12-20 2023-03-14 南通联亚药业股份有限公司 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN116036033A (zh) * 2023-01-06 2023-05-02 青岛润昕德生物医药有限公司 一种地屈孕酮片及其生产工艺
IT202300027360A1 (it) * 2023-12-20 2025-06-20 Lesaffre & Cie Formulazioni solide di folati
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
JP4334616B2 (ja) 1994-09-22 2009-09-30 ナームローゼ・フエンノートチヤツプ・オルガノン 湿式粒状化による投与単位体を製造する方法
RU2073529C1 (ru) * 1995-05-16 1997-02-20 Центральный научно-исследовательский рентгенорадиологический институт Композиция для эмболизации кровеносных сосудов
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
SK287634B6 (sk) * 1999-08-31 2011-04-05 Bayer Schering Pharma Aktiengesellschaft Farmaceutická kompozícia obsahujúca drospirenón a etinylestradiol a farmaceutický prípravok
SI1214076T1 (en) * 1999-08-31 2004-06-30 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
ATE442147T1 (de) * 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
US6550482B1 (en) * 2000-04-21 2003-04-22 Vascular Control Systems, Inc. Methods for non-permanent occlusion of a uterine artery
US6864774B2 (en) 2000-10-19 2005-03-08 Matsushita Electric Industrial Co., Ltd. Inductance component and method of manufacturing the same
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
BR0215613A (pt) * 2002-02-21 2004-12-07 Schering Ag Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12
CA2503949C (en) * 2002-10-29 2012-10-23 Toray Industries, Inc. Embolization material
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
KR20090029824A (ko) * 2006-07-06 2009-03-23 바이엘 쉐링 파마 악티엔게젤샤프트 피임용 및 선천성 기형 위험 예방용 제약 제제
RU62008U1 (ru) * 2006-10-13 2007-03-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
RU61120U1 (ru) * 2006-10-13 2007-02-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block

Also Published As

Publication number Publication date
AU2007271449A1 (en) 2008-01-10
EP2422774A1 (en) 2012-02-29
IL245355A0 (en) 2016-06-30
EP2040683A1 (en) 2009-04-01
ES2626838T5 (es) 2024-03-14
CU20090004A7 (es) 2011-07-11
JP2009542591A (ja) 2009-12-03
TWI508730B (zh) 2015-11-21
TW201538161A (zh) 2015-10-16
GT200900001A (es) 2009-12-08
CU23902B1 (https=) 2013-06-28
IL245355B (en) 2019-05-30
RU2012133154A (ru) 2014-02-10
NO20090578A (no) 2009-03-09
WO2008003432A1 (en) 2008-01-10
NO20090578L (no) 2009-03-09
PH12012501774A1 (en) 2015-09-21
UA100228C2 (uk) 2012-12-10
TNSN08543A1 (en) 2010-04-14
SG188869A1 (en) 2013-04-30
CN101484143B (zh) 2012-07-04
CL2007001962A1 (es) 2008-01-04
ECSP099030A (es) 2009-02-27
PE20120375A1 (es) 2012-05-23
MX2009000079A (es) 2009-01-23
BRPI0713565B1 (pt) 2021-02-02
ZA200900868B (en) 2021-05-26
CN102813663A (zh) 2012-12-12
KR20130042638A (ko) 2013-04-26
UA105078C2 (uk) 2014-04-10
UY30462A1 (es) 2008-02-29
ZA201808084B (en) 2021-06-30
IL224484A (en) 2016-05-31
CN102813663B (zh) 2019-03-22
AR061958A1 (es) 2008-08-10
IL196027A0 (en) 2009-09-01
CN101484143A (zh) 2009-07-15
PH12012501774B1 (en) 2015-09-21
EP2422774B1 (en) 2015-08-12
CA2856344A1 (en) 2008-01-10
EP2040683B2 (en) 2023-08-16
RU2624236C2 (ru) 2017-07-03
CA2656131A1 (en) 2008-01-10
CR10549A (es) 2009-01-27
NZ573766A (en) 2011-05-27
RU2009103649A (ru) 2010-08-20
HK1131917A1 (en) 2010-02-12
AU2007271449B2 (en) 2013-07-11
TW200812593A (en) 2008-03-16
CA2856344C (en) 2017-02-28
CA2656131C (en) 2015-10-13
ZA201808083B (en) 2021-06-30
EP2040683B1 (en) 2017-03-01
AR106561A2 (es) 2018-01-24
MY169516A (en) 2019-04-22
CO6150125A2 (es) 2010-04-20
ZA201501673B (en) 2016-02-24
KR20090033889A (ko) 2009-04-06
BRPI0713565B8 (pt) 2021-05-25
MA30598B1 (fr) 2009-07-01
ES2626838T3 (es) 2017-07-26
PE20080273A1 (es) 2008-05-16
NO347567B1 (no) 2024-01-15
BRPI0713565A2 (pt) 2012-03-20
RU2479306C2 (ru) 2013-04-20
CN101489563A (zh) 2009-07-22

Similar Documents

Publication Publication Date Title
PE20150287A1 (es) Composicion farmaceutica que contiene un acido tetrahidrofolico
MX385798B (es) Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados.
PE20070208A1 (es) Anticoncepcion oral con trimegestona
TW200837074A (en) Extended triterpene derivatives
BR0317275A (pt) Liberação controlada de uma substância ativa em um ambiente de gordura alta
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
CY1109910T1 (el) Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων
BR112013006597A2 (pt) tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo
JP2009528372A5 (https=)
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
EA201201403A1 (ru) Очень низкодозированные твердые пероральные лекарственные формы для гзт
GT200000170A (es) Agentes terapeuticos.
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
NZ605176A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
PE20130657A1 (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
AR111649A1 (es) Anillo vaginal para la liberación simultánea de dos ingredientes activos
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
PE20060318A1 (es) Forma de administracion para la contracepcion hormonal
FI3345604T3 (fi) Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa
WO2010089259A3 (en) Sustained release composition containing quetiapine

Legal Events

Date Code Title Description
FG Grant, registration